Tabrecta shows promise in Real-World lung cancer study
NCT ID NCT04575025
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tracked 109 patients with a specific genetic mutation (MET exon 14 skipping) causing advanced lung cancer who were prescribed Tabrecta tablets. Researchers monitored side effects and how well the drug controlled the cancer over up to one year. The goal was to see how Tabrecta works in everyday medical practice, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tabrecta (capmatinib) tablets
What this could lead to
If results confirm benefit, this could support Tabrecta as a standard treatment for MET exon 14 skipping mutation-positive advanced lung cancer.
What could go wrong
This is an observational study without a control group, so results are less definitive. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kōnan, Aichi-ken, 4838704, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 457-0818, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 462-0057, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 464 8681, Japan
-
Novartis Investigative Site
Okazaki, Aichi-ken, 444-8553, Japan
-
Novartis Investigative Site
Toyoake, Aichi-ken, 470 1192, Japan
-
Novartis Investigative Site
Toyota, Aichi-ken, 470-0343, Japan
-
Novartis Investigative Site
Daisen, Akita, 014-0027, Japan
-
Novartis Investigative Site
Hachinohe, Aomori, 031-0011, Japan
-
Novartis Investigative Site
Sakura, Chiba, 285-8741, Japan
-
Novartis Investigative Site
Fukui-shi, Fukui, 918-8501, Japan
-
Novartis Investigative Site
Yoshida-gun, Fukui, 910-1193, Japan
-
Novartis Investigative Site
Fukuoka, Fukuoka, 811-1395, Japan
-
Novartis Investigative Site
Fukuoka, Fukuoka, 812-8582, Japan
-
Novartis Investigative Site
Fukuoka, Fukuoka, 814 0180, Japan
-
Novartis Investigative Site
Iizuka, Fukuoka, 820-0076, Japan
-
Novartis Investigative Site
Kitakyushu, Fukuoka, 802-0077, Japan
-
Novartis Investigative Site
Kitakyushu, Fukuoka, 8058508, Japan
-
Novartis Investigative Site
Kitakyushu, Fukuoka, 806-8501, Japan
-
Novartis Investigative Site
Fukushima, Fukushima, 960 1295, Japan
-
Novartis Investigative Site
Ōgaki, Gifu, 503-8502, Japan
-
Novartis Investigative Site
Higashihiroshima, Hiroshima, 739-0041, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 003-0804, Japan
-
Novartis Investigative Site
Akashi, Hyōgo, 673-8558, Japan
-
Novartis Investigative Site
Himeji, Hyōgo, 670-8520, Japan
-
Novartis Investigative Site
Nishinomiya, Hyōgo, 663 8501, Japan
-
Novartis Investigative Site
Tsuchiura, Ibaraki, 300-0028, Japan
-
Novartis Investigative Site
Tsukuba, Ibaraki, 305-8558, Japan
-
Novartis Investigative Site
Kan’onjichō, Kagawa-ken, 769-1695, Japan
-
Novartis Investigative Site
Sakaidechō, Kagawa-ken, 762-8550, Japan
-
Novartis Investigative Site
Takamatsu, Kagawa-ken, 760-0017, Japan
-
Novartis Investigative Site
Fujisawa, Kanagawa, 251-8550, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 216-8511, Japan
-
Novartis Investigative Site
Sagamihara, Kanagawa, 252-0375, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 220-8521, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 221-0855, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 232 0024, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 234-0054, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 236 0037, Japan
-
Novartis Investigative Site
Tsu, Mie-ken, 514-8507, Japan
-
Novartis Investigative Site
Yokkaichi, Mie-ken, 510-8567, Japan
-
Novartis Investigative Site
Miyakonojō, Miyazaki, 885-0014, Japan
-
Novartis Investigative Site
Matsumoto, Nagano, 390-8621, Japan
-
Novartis Investigative Site
Nagasaki, Nagasaki, 852-8501, Japan
-
Novartis Investigative Site
Kurashiki, Okayama-ken, 701-0192, Japan
-
Novartis Investigative Site
Okayama, Okayama-ken, 700-8558, Japan
-
Novartis Investigative Site
Kishiwada, Osaka, 596-8501, Japan
-
Novartis Investigative Site
Osaka, Osaka, 534-0021, Japan
-
Novartis Investigative Site
Osaka, Osaka, 540-0006, Japan
-
Novartis Investigative Site
Osaka, Osaka, 541-8567, Japan
-
Novartis Investigative Site
Osaka, Osaka, 543-8555, Japan
-
Novartis Investigative Site
Saga, Saga-ken, 849-8501, Japan
-
Novartis Investigative Site
Kawaguchi, Saitama, 332-8558, Japan
-
Novartis Investigative Site
Kumagaya, Saitama, 360-0197, Japan
-
Novartis Investigative Site
Saitama, Saitama, 330 8503, Japan
-
Novartis Investigative Site
Saitama, Saitama, 330-8553, Japan
-
Novartis Investigative Site
Izumo, Shimane, 693 8501, Japan
-
Novartis Investigative Site
Hamamatsu, Shizuoka, 431-3192, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 113-8431, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 0045, Japan
-
Novartis Investigative Site
Edogawa City, Tokyo, 133-0052, Japan
-
Novartis Investigative Site
Kiyose, Tokyo, 204-8585, Japan
-
Novartis Investigative Site
Koto Ku, Tokyo, 135 8550, Japan
-
Novartis Investigative Site
Minato, Tokyo, 108-0073, Japan
-
Novartis Investigative Site
Minato Ku, Tokyo, 105-8470, Japan
-
Novartis Investigative Site
Minato-ku, Tokyo, 105-8471, Japan
-
Novartis Investigative Site
Shibuya City, Tokyo, 150-8935, Japan
-
Novartis Investigative Site
Shinjuku Ku, Tokyo, 160-0023, Japan
-
Novartis Investigative Site
Tama, Tokyo, 206-8512, Japan
-
Novartis Investigative Site
Toyama, Toyama, 930-0194, Japan
-
Novartis Investigative Site
Higashi Okitama, Yamagata, 9920601, Japan
-
Novartis Investigative Site
Ube, Yamaguchi, 755-0241, Japan
-
Novartis Investigative Site
Aomori, 030 8553, Japan
-
Novartis Investigative Site
Chiba, 261-0001, Japan
-
Novartis Investigative Site
Hiroshima, 734 8530, Japan
-
Novartis Investigative Site
Kumamoto, 860-8556, Japan
-
Novartis Investigative Site
Kumamoto, 861-4193, Japan
-
Novartis Investigative Site
Osaka, 530 0005, Japan